Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) Short Interest Down 8.3% in August

Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) was the recipient of a large drop in short interest during the month of August. As of August 31st, there was short interest totalling 25,500 shares, a drop of 8.3% from the July 31st total of 27,800 shares. Currently, 2.1% of the company’s stock are short sold. Based on an average daily trading volume, of 14,900 shares, the short-interest ratio is currently 1.7 days.

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Liberty Wealth Management LLC purchased a new position in shares of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 4,188 shares of the company’s stock, valued at approximately $33,000. Liberty Wealth Management LLC owned 0.31% of Sonoma Pharmaceuticals at the end of the most recent reporting period. 6.05% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:SNOA remained flat at $$6.20 during trading hours on Friday. 517 shares of the company were exchanged, compared to its average volume of 7,192. The firm’s fifty day moving average is $6.39 and its 200-day moving average is $3.32. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.35 and a quick ratio of 2.53. Sonoma Pharmaceuticals has a 12-month low of $4.85 and a 12-month high of $25.20.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its quarterly earnings results on Monday, July 8th. The company reported ($2.45) earnings per share for the quarter. The business had revenue of $4.38 million for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 66.14% and a negative net margin of 39.48%.

Separately, ValuEngine upgraded shares of Sonoma Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions.

Recommended Story: Understanding Stock Ratings

Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.